What did @lwwkate218 actually say?
Honestly? Almost nothing medically substantive. The transcript is essentially camera-test audio: "Oh, oh, oh, oh! It's all about camera. And baby!" The real content lives in the caption, where the creator shares a starting weight of 218.2 pounds, a goal weight of 135 pounds, and identifies the drug as "Semiglutide" (a common misspelling of semaglutide). She also tags it under GLP and injections, framing this as a week-one documentation of a weight-loss journey.
So there are no spoken medical claims to fact-check here. What we can evaluate is the framing: a 1.1 million-view video presenting GLP-1 therapy as an exciting personal journey, with a goal weight deficit of over 83 pounds. That framing carries its own set of assumptions worth unpacking.
Does the science back this up?
The drug she is likely referring to, semaglutide, has solid clinical backing for weight loss, though the reality is more complicated than a starting-weight caption suggests. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed participants on 2.4 mg weekly semaglutide lost an average of 14.9% of body weight over 68 weeks.
That is meaningful. But "average" is doing a lot of work in that sentence. A subset of patients loses significantly less, and some plateau early. The STEP 4 trial (Rubino et al., 2021, JAMA) showed that when people stopped semaglutide, they regained about two-thirds of the weight lost within a year. The drug works, largely, while you take it. Whether the creator is on brand-name Wegovy, compounded semaglutide, or something else entirely is unknown from the video, and that distinction matters for dosing consistency and regulatory oversight.
What did they get wrong (or right)?
The misspelling "Semiglutide" in the caption is a minor error but worth flagging because 1.1 million people saw that hashtag. Misspellings in health content create fragmented information ecosystems where people searching the correct term miss related content and vice versa.
The 83-pound goal is not inherently wrong to have, but presenting it without any timeline or clinical context in a high-reach video normalizes aggressive weight targets without acknowledging individual metabolic variation. Research from Tchang et al. (2023, Obesity Reviews) notes that expectations for GLP-1 therapy frequently exceed clinical outcomes, which can lead to early discontinuation when results feel disappointing.
What she got right: documenting a starting point before treatment is actually a reasonable practice. Tracking baseline weight gives patients and clinicians a reference point. There is nothing medically problematic about beginning a progress diary.
What should you actually know?
If you are watching this video and considering semaglutide, here are the things the caption did not tell you. First, the drug requires a prescription and ongoing medical supervision. Second, compounded semaglutide, which is widely available through telehealth platforms, is not the same as FDA-approved Wegovy or Ozempic. The FDA has flagged compounded versions for quality inconsistencies (FDA Drug Shortages guidance, updated 2024).
Third, side effects in week one are common and sometimes severe. Nausea, vomiting, and gastrointestinal distress affect a significant proportion of new users, particularly at higher starting doses. The STEP trials reported nausea in roughly 44% of participants. Fourth, a goal weight is not a clinical prescription. Healthy target weight depends on body composition, metabolic history, age, and other factors that a TikTok caption cannot capture.
Finally: the excitement in this video is understandable. Starting a new treatment with a clear goal feels motivating. But 1.1 million viewers deserve to know that the journey between week one and goal weight is rarely as linear as a before-photo implies.